Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial
| Autor: | João Pedro Ferreira, Piotr Ponikowski, Muhammad Shahzeb Khan, Stefan D. Anker, Stuart J. Pocock, Milton Packer, Gerasimos Filippatos, Naveed Sattar, Javed Butler, Martina Brueckmann, EMPEROR-Reduced Trial Committees, Subodh Verma, James L. Januzzi, Faiez Zannad, Ola Vedin, Ileana L. Piña, Nadia Giannetti, Waheed Jamal, Barbara Peil, Cordula Zeller, Carolyn S.P. Lam, Investigators |
|---|---|
| Přispěvatelé: | University of Mississippi Medical Center (UMMC), Berlin-Brandenburg Center for Regenerative Therapies [Berlin, Germany], Charité - UniversitätsMedizin = Charité - University Hospital [Berlin], German Centre for Cardiovascular Research (DZHK) partner site Berlin, National and Kapodistrian University of Athens (NKUA), Centre d'investigation clinique plurithématique Pierre Drouin [Nancy] (CIC-P), Centre d'investigation clinique [Nancy] (CIC), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL)-Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), Défaillance Cardiovasculaire Aiguë et Chronique (DCAC), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), Cardiovascular and Renal Clinical Trialists [Vandoeuvre-les-Nancy] (INI-CRCT), Institut Lorrain du Coeur et des Vaisseaux Louis Mathieu [Nancy], French-Clinical Research Infrastructure Network - F-CRIN [Paris] (Cardiovascular & Renal Clinical Trialists - CRCT ), Department of Medical Statistics, London School of Hygiene & Tropical Medicine, McGill University Health Center [Montreal] (MUHC), Massachusetts General Hospital [Boston], Department of Medicine, Wayne State and Central Michigan Universities, National University of Singapore (NUS), Centre for Heart Diseases, Wroclaw Medical University, BHF Cardiovascular Research Centre, Institute of Cardiovascular and Medical Sciences, University of Glasgow, Division of Cardiac Surgery, St Michael's Hospital, University of Toronto, Boehringer Ingelheim International GmbH, Universität Heidelberg [Heidelberg], Boehringer Ingelheim AB, Boehringer Ingelheim Pharmaceuticals, Boehringer Ingelheim Pharma GmbH & Co, Cardiovascular Science, Baylor Heart and Vascular Institute, Baylor University Medical Center, Faculty of Medicine, National Heart and Lung Institute, Imperial College, The EMPEROR-Reduced trial was funded by the Boehringer Ingelheim & Eli Lilly and Company Diabetes Alliance, BOZEC, Erwan, Université de Lorraine (UL)-Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL)-Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université de Lorraine (UL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), National Heart Centre Singapore & Duke-National University of Singapore, Faculty of Medicine Mannheim, University of Heidelberg |
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Quality of life
medicine.medical_specialty Empagliflozin 030204 cardiovascular system & hematology Health status 03 medical and health sciences 0302 clinical medicine [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system Glucosides Internal medicine Patient-Centered Care medicine Humans AcademicSubjects/MED00200 030212 general & internal medicine Benzhydryl Compounds Heart Failure and Cardiomyopathies Heart Failure Ejection fraction Proportional hazards model business.industry Hazard ratio Clnical Research Stroke Volume Odds ratio medicine.disease 3. Good health [SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system Clinical trial Heart failure Cardiology Cardiology and Cardiovascular Medicine business SGLT2 inhibitors |
| Zdroj: | European Heart Journal European Heart Journal, Oxford University Press (OUP), 2021, ⟨10.1093/eurheartj/ehaa1007⟩ European Heart Journal, Oxford University Press (OUP): Policy B, 2021, ⟨10.1093/eurheartj/ehaa1007⟩ |
| ISSN: | 1522-9645 0195-668X |
| DOI: | 10.1093/eurheartj/ehaa1007⟩ |
| Popis: | Aims In this secondary analysis of the EMPEROR-Reduced trial, we sought to evaluate whether the benefits of empagliflozin varied by baseline health status and how empagliflozin impacted patient-reported outcomes in patients with heart failure with reduced ejection fraction. Methods and results Health status was assessed by the Kansas City Cardiomyopathy Questionnaires-clinical summary score (KCCQ-CSS). The influence of baseline KCCQ-CSS (analyzed by tertiles) on the effect of empagliflozin on major outcomes was examined using Cox proportional hazards models. Responder analyses were performed to assess the odds of improvement and deterioration in KCCQ scores related to treatment with empagliflozin. Empagliflozin reduced the primary outcome of cardiovascular death or heart failure hospitalization regardless of baseline KCCQ-CSS tertiles [hazard ratio (HR) 0.83 (0.68–1.02), HR 0.74 (0.58–0.94), and HR 0.61 (0.46–0.82) for Graphical abstract |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|